Research progress of continuous renal replacement therapy in rhabdomyolysis-induced acute kidney injury_West China Medical Journal

Authors：

CHEN Xingu ¹ ,  ZHOU Xiaoshuang ²

1. The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi 030012, P. R. China;
2. Department of Nephrology, Shanxi Provincial People’s Hospital / the Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi 030012, P. R. China;

Corresponding author：

ZHOU Xiaoshuang, Email: xiaoshuangzhou66@163.com

Keywords：

Continuous renal replacement therapy; rhabdomyolysis; acute kidney injury

DOI：

10.7507/1002-0179.202307014

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Rhabdomyolysis-induced acute kidney injury (RIAKI) is a serious clinical disease in intensive care unit, characterized by high mortality and low cure rate. Continuous renal replacement therapy (CRRT) is a common form of treatment for RIAKI. There are currently no guidelines to guide the application of CRRT in RIAKI. To solve this problem, this article reviews the advantages and limitations of CRRT in the treatment of RIAKI, as well as new viewpoints and research progress in the selection of treatment timing, treatment mode, treatment dose and filtration membrane, with the aim of providing theoretical guidance for the treatment of CRRT in RIAKI patients.

Citation： CHEN Xingu, ZHOU Xiaoshuang. Research progress of continuous renal replacement therapy in rhabdomyolysis-induced acute kidney injury. West China Medical Journal, 2023, 38(10): 1590-1594. doi: 10.7507/1002-0179.202307014 Copy

1.	Hebert JF, Burfeind KG, Malinoski D, et al. Molecular mechanisms of rhabdomyolysis-induced kidney injury: from bench to bedside. Kidney Int Rep, 2022, 8(1): 17-29.
2.	Boudhabhay I, Poillerat V, Grunenwald A, et al. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney Int, 2021, 99(3): 581-597.
3.	Yang CW, Li S, Dong Y, et al. Epidemiology and the impact of acute kidney injury on outcomes in patients with rhabdomyolysis. J Clin Med, 2021, 10(9): 1950.
4.	Yang J, Zhou J, Wang X, et al. Risk factors for severe acute kidney injury among patients with rhabdomyolysis. BMC Nephrol, 2020, 21(1): 498.
5.	Long B, Koyfman A, Gottlieb M. An evidence-based narrative review of the emergency department evaluation and management of rhabdomyolysis. Am J Emerg Med, 2019, 37(3): 518-523.
6.	Secombe P, Milne C. Hyponatraemia-induced rhabdomyolysis complicated by anuric acute kidney injury: a renal replacement conundrum. BMJ Case Rep, 2016, 2016: bcr2016218198.
7.	Swaroop R, Zabaneh R, Parimoo N. Plasmapheresis in a patient with rhabdomyolysis: a case report. Cases J, 2009, 2: 8138.
8.	Moresco E, Rugg C, Ströhle M, et al. Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb^® ): a case report. Clin Case Rep, 2022, 10(1): e05272.
9.	Gong J, Yuan H, Gao Z, et al. Wasp venom and acute kidney injury: the mechanisms and therapeutic role of renal replacement therapy. Toxicon, 2019, 163: 1-7.
10.	Cruz DN, Bagshaw SM. Does continuous renal replacement therapy have a role in the treatment of rhabdomyolysis complicated by acute kidney injury?. Semin Dial, 2011, 24(4): 417-420.
11.	Muaddi L, Ledgerwood C, Sheridan R, et al. Acute renal failure and its complications, indications for emergent dialysis, and dialysis modalities. Crit Care Nurs Q, 2022, 45(3): 258-265.
12.	Matsushita K, Mori K, Saritas T, et al. Cilastatin ameliorates rhabdomyolysis-induced AKI in mice. J Am Soc Nephrol, 2021, 32(10): 2579-2594.
13.	Muratsu J, Sanada F, Koibuchi N, et al. Blocking periostin prevented development of inflammation in rhabdomyolysis-induced acute kidney injury mice model. Cells, 2022, 11(21): 3388.
14.	Wang J, Xu G, Jin H, et al. Ulinastatin alleviates rhabdomyolysis-induced acute kidney injury by suppressing inflammation and apoptosis via inhibiting TLR4/NF-κB signaling pathway. Inflammation, 2022, 45(5): 2052-2065.
15.	Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care, 2014, 18(3): 224.
16.	Nielsen FE, Cordtz JJ, Rasmussen TB, et al. The association between rhabdomyolysis, acute kidney injury, renal replacement therapy, and mortality. Clin Epidemiol, 2020, 12: 989-995.
17.	Li X, Bai M, Yu Y, et al. Earlier continuous renal replacement therapy is associated with reduced mortality in rhabdomyolysis patients. Ren Fail, 2022, 44(1): 1743-1753.
18.	陈德政, 张凌, 李明鹏, 等. 连续性肾脏替代治疗在蜂蜇伤致横纹肌溶解合并急性肾损伤中的应用. 华西医学, 2018, 33(7): 848-851.
19.	Tang W, Chen Z, Wu W, et al. Renal protective effects of early continuous venovenous hemofiltration in rhabdomyolysis: improved renal mitochondrial dysfunction and inhibited apoptosis. Artif Organs, 2013, 37(4): 390-400.
20.	Moore PK, Hsu RK, Liu KD, et al. Management of acute kidney injury: core curriculum 2018. Am J Kidney Dis, 2018, 72(1): 136-148.
21.	Scharf C, Liebchen U, Paal M, et al. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit Care, 2021, 25(1): 41.
22.	Xiao L, Ran X, Zhong Y, et al. Serum creatine kinase levels are not associated with an increased need for continuous renal replacement therapy in patients with acute kidney injury following rhabdomyolysis. Ren Fail, 2022, 44(1): 893-901.
23.	Sorrentino SA, Kielstein JT, Lukasz A, et al. High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med, 2011, 39(1): 184-186.
24.	Keir R, Evans ND, Hutchison CA, et al. Kinetic modelling of haemodialysis removal of myoglobin in rhabdomyolysis patients. Comput Methods Programs Biomed, 2014, 114(3): e29-38.
25.	Weidhase L, de Fallois J, Haußig E, et al. Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Crit Care, 2020, 24(1): 644.
26.	Hui WF, Chan RWY, Wong CK, et al. The sequential use of extracorporeal cytokine removal devices in an adolescent with COVID-19 receiving continuous renal replacement therapy. ASAIO J, 2022, 68(12): e230-e234.
27.	Jerman A, Andonova M, Persic V, et al. Extracorporeal removal of myoglobin in patients with rhabdomyolysis and acute kidney injury: comparison of high and medium cut-off membrane and an adsorber cartridge. Blood Purif, 2022, 51(11): 907-911.
28.	Mariano F, Mella A, Rumbolo F, et al. Clearance of NT-proBNP and procalcitonin during continuous venovenous hemodialysis with the medium cutoff filter in patients with rhabdomyolysis-associated early acute kidney injury. Blood Purif, 2023, 52(5): 446-454.
29.	Xu Q, Jiang B, Li J, et al. Comparison of filter life span and solute removal during continuous renal replacement therapy: convection versus diffusion - A randomized controlled trial. Ther Apher Dial, 2022, 26(5): 1030-1039.
30.	邓莉莉, 曹丹. 比较不同模式下 CRRT 治疗横纹肌溶解综合征合并急性肾损伤的疗效. 现代医药卫生, 2019, 35(7): 1047-1049.
31.	Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet, 2000, 356(9223): 26-30.
32.	VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med, 2008, 359(1): 7-20.
33.	Joannes-Boyau O, Honoré PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med, 2013, 39(9): 1535-1546.
34.	Jentzer JC, Bihorac A, Brusca SB, et al. Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome: JACC council perspectives. J Am Coll Cardiol, 2020, 76(9): 1084-1101.
35.	Küllmar M, Zarbock A. Nierenersatzverfahren bei akuter Nierenschädigung: Von der Indikation bis zur Beendigung. Anaesthesist, 2019, 68(7): 485-496.
36.	Bagshaw SM, Chakravarthi MR, Ricci Z, et al. Precision continuous renal replacement therapy and solute control. Blood Purif, 2016, 42(3): 238-247.

1. Hebert JF, Burfeind KG, Malinoski D, et al. Molecular mechanisms of rhabdomyolysis-induced kidney injury: from bench to bedside. Kidney Int Rep, 2022, 8(1): 17-29.
2. Boudhabhay I, Poillerat V, Grunenwald A, et al. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney Int, 2021, 99(3): 581-597.
3. Yang CW, Li S, Dong Y, et al. Epidemiology and the impact of acute kidney injury on outcomes in patients with rhabdomyolysis. J Clin Med, 2021, 10(9): 1950.
4. Yang J, Zhou J, Wang X, et al. Risk factors for severe acute kidney injury among patients with rhabdomyolysis. BMC Nephrol, 2020, 21(1): 498.
5. Long B, Koyfman A, Gottlieb M. An evidence-based narrative review of the emergency department evaluation and management of rhabdomyolysis. Am J Emerg Med, 2019, 37(3): 518-523.
6. Secombe P, Milne C. Hyponatraemia-induced rhabdomyolysis complicated by anuric acute kidney injury: a renal replacement conundrum. BMJ Case Rep, 2016, 2016: bcr2016218198.
7. Swaroop R, Zabaneh R, Parimoo N. Plasmapheresis in a patient with rhabdomyolysis: a case report. Cases J, 2009, 2: 8138.
8. Moresco E, Rugg C, Ströhle M, et al. Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb^® ): a case report. Clin Case Rep, 2022, 10(1): e05272.
9. Gong J, Yuan H, Gao Z, et al. Wasp venom and acute kidney injury: the mechanisms and therapeutic role of renal replacement therapy. Toxicon, 2019, 163: 1-7.
10. Cruz DN, Bagshaw SM. Does continuous renal replacement therapy have a role in the treatment of rhabdomyolysis complicated by acute kidney injury?. Semin Dial, 2011, 24(4): 417-420.
11. Muaddi L, Ledgerwood C, Sheridan R, et al. Acute renal failure and its complications, indications for emergent dialysis, and dialysis modalities. Crit Care Nurs Q, 2022, 45(3): 258-265.
12. Matsushita K, Mori K, Saritas T, et al. Cilastatin ameliorates rhabdomyolysis-induced AKI in mice. J Am Soc Nephrol, 2021, 32(10): 2579-2594.
13. Muratsu J, Sanada F, Koibuchi N, et al. Blocking periostin prevented development of inflammation in rhabdomyolysis-induced acute kidney injury mice model. Cells, 2022, 11(21): 3388.
14. Wang J, Xu G, Jin H, et al. Ulinastatin alleviates rhabdomyolysis-induced acute kidney injury by suppressing inflammation and apoptosis via inhibiting TLR4/NF-κB signaling pathway. Inflammation, 2022, 45(5): 2052-2065.
15. Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care, 2014, 18(3): 224.
16. Nielsen FE, Cordtz JJ, Rasmussen TB, et al. The association between rhabdomyolysis, acute kidney injury, renal replacement therapy, and mortality. Clin Epidemiol, 2020, 12: 989-995.
17. Li X, Bai M, Yu Y, et al. Earlier continuous renal replacement therapy is associated with reduced mortality in rhabdomyolysis patients. Ren Fail, 2022, 44(1): 1743-1753.
18. 陈德政, 张凌, 李明鹏, 等. 连续性肾脏替代治疗在蜂蜇伤致横纹肌溶解合并急性肾损伤中的应用. 华西医学, 2018, 33(7): 848-851.
19. Tang W, Chen Z, Wu W, et al. Renal protective effects of early continuous venovenous hemofiltration in rhabdomyolysis: improved renal mitochondrial dysfunction and inhibited apoptosis. Artif Organs, 2013, 37(4): 390-400.
20. Moore PK, Hsu RK, Liu KD, et al. Management of acute kidney injury: core curriculum 2018. Am J Kidney Dis, 2018, 72(1): 136-148.
21. Scharf C, Liebchen U, Paal M, et al. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit Care, 2021, 25(1): 41.
22. Xiao L, Ran X, Zhong Y, et al. Serum creatine kinase levels are not associated with an increased need for continuous renal replacement therapy in patients with acute kidney injury following rhabdomyolysis. Ren Fail, 2022, 44(1): 893-901.
23. Sorrentino SA, Kielstein JT, Lukasz A, et al. High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med, 2011, 39(1): 184-186.
24. Keir R, Evans ND, Hutchison CA, et al. Kinetic modelling of haemodialysis removal of myoglobin in rhabdomyolysis patients. Comput Methods Programs Biomed, 2014, 114(3): e29-38.
25. Weidhase L, de Fallois J, Haußig E, et al. Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Crit Care, 2020, 24(1): 644.
26. Hui WF, Chan RWY, Wong CK, et al. The sequential use of extracorporeal cytokine removal devices in an adolescent with COVID-19 receiving continuous renal replacement therapy. ASAIO J, 2022, 68(12): e230-e234.
27. Jerman A, Andonova M, Persic V, et al. Extracorporeal removal of myoglobin in patients with rhabdomyolysis and acute kidney injury: comparison of high and medium cut-off membrane and an adsorber cartridge. Blood Purif, 2022, 51(11): 907-911.
28. Mariano F, Mella A, Rumbolo F, et al. Clearance of NT-proBNP and procalcitonin during continuous venovenous hemodialysis with the medium cutoff filter in patients with rhabdomyolysis-associated early acute kidney injury. Blood Purif, 2023, 52(5): 446-454.
29. Xu Q, Jiang B, Li J, et al. Comparison of filter life span and solute removal during continuous renal replacement therapy: convection versus diffusion - A randomized controlled trial. Ther Apher Dial, 2022, 26(5): 1030-1039.
30. 邓莉莉, 曹丹. 比较不同模式下 CRRT 治疗横纹肌溶解综合征合并急性肾损伤的疗效. 现代医药卫生, 2019, 35(7): 1047-1049.
31. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet, 2000, 356(9223): 26-30.
32. VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med, 2008, 359(1): 7-20.
33. Joannes-Boyau O, Honoré PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med, 2013, 39(9): 1535-1546.
34. Jentzer JC, Bihorac A, Brusca SB, et al. Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome: JACC council perspectives. J Am Coll Cardiol, 2020, 76(9): 1084-1101.
35. Küllmar M, Zarbock A. Nierenersatzverfahren bei akuter Nierenschädigung: Von der Indikation bis zur Beendigung. Anaesthesist, 2019, 68(7): 485-496.
36. Bagshaw SM, Chakravarthi MR, Ricci Z, et al. Precision continuous renal replacement therapy and solute control. Blood Purif, 2016, 42(3): 238-247.

West China Medical Journal

Research progress of continuous renal replacement therapy in rhabdomyolysis-induced acute kidney injury

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content